PER percheron therapeutics limited

EQUITY RESEARCH REPORT - WILSON dated 18 Jan 2022, page-5

  1. 3,323 Posts.
    lightbulb Created with Sketch. 321
    Everything on words is good but meantime there has been the J.P. Morgan conference in San Francisco one (if not the) of the most important conference in the bio/pharma world and no sign or whatsoever from the management of Antisense ANP the company that supposedly will OWN the DMD SPACE as loud and clearly said on the last AGM.
    I am speechless and incredulous to such “unexpected” oversight
    Last edited by imperatore: 18/01/22
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.8¢
Change
-0.001(5.88%)
Mkt cap ! $8.699M
Open High Low Value Volume
0.8¢ 0.8¢ 0.8¢ $2.01K 251.2K

Buyers (Bids)

No. Vol. Price($)
9 4817091 0.8¢
 

Sellers (Offers)

Price($) Vol. No.
0.9¢ 1969872 4
View Market Depth
Last trade - 15.47pm 04/07/2025 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.